Modis Therapeutics, Inc., a company developing medicines for patients with rare genetic diseases, raised a $30 million Series A investment led by F-Prime Capital Partners and OrbiMed. Modis is advancing its lead experimental therapy, MT1621, as a treatment for thymidine kinase 2 deficiency (TK2d), a